Bio-Thera Solutions

Company snapshot

Bio-Thera Solutions is a clinical-stage pharmaceutical company focused on biologic therapeutics. Bio-Thera is developing a pipeline on innovative enhanced monoclonal antibodies and antibody-drug conjugates for the treatment of a broad range of cancers and other diseases as well as a pipeline of biosimilars in the autoimmune and oncology therapeutic areas. The company is headquartered in Guangzhou,

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Bio-Thera Solutions. Not investment advice.

• approval Jun 11, 2026

  FDA Approves First Interchangeable Biosimilars to Simponi and Simponi Aria

• What is Bio-Thera Solutions?

  Bio-Thera Solutions is a pharma organization headquartered in CN. Primary therapeutic focus areas include Diabetic Macular Edema (DME). NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, a

• Is Bio-Thera Solutions publicly traded?

  Bio-Thera Solutions appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Bio-Thera Solutions develop or market?

  We link 2 drug profile(s) where Bio-Thera Solutions is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/bio-thera-solutions#company-drugs.

• What are the latest developments for Bio-Thera Solutions?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Bio-Thera Solutions focus on?

  Bio-Thera Solutions focuses on Diabetic Macular Edema (DME) based on our analysis of their pipeline programs and drug development activities.